This opportunity uses the R21/R23 Phased Innovation Award funding mechanism.
Applications are invited to support early stage translational research focused on the discovery and development of novel therapeutics against select eukaryotic pathogens.
Funding & Duration
Application budgets are limited to US $275,000 (approx. AUD $380,000) in direct costs over the two-year project period, with a maximum of $200,000 (approx. AUD $276,000) in direct costs allowed in any single year.
The R33 award phase is limited to $300,000 (approx. AUD $414,000) in direct costs per year.
Eligibility
Non-domestic (non-U.S.) Entities (Foreign Institutions) are eligible to apply.
Submission Requirements & Due Dates
- 10 January 2016 – Letter of Intent (LOI) via Grants.Gov submission portal.
- Copy of LOI forwarded to the Research Branch ASAP.
- 27 January 2016 – full applications (by invitation only) submitted to the Research Branch for internal review.
Grants Officer: Dr Don McMaster
Email: don.mcmaster@adelaide.edu.au